Struggling Sea Lions May Benefit from UCSF Neuroscience Research
A cellular therapy for epilepsy developed at UCSF has been employed for the first time in a sea lion with intractable seizures caused by ingesting toxins from algal blooms.
University of California San Francisco
Give to UCSFA cellular therapy for epilepsy developed at UCSF has been employed for the first time in a sea lion with intractable seizures caused by ingesting toxins from algal blooms.
Older adults who took weekly 15-minute “awe walks” for eight weeks reported increased positive emotions and less distress in their daily lives.
The achievement of “plug and play” performance demonstrates the value of so-called ECoG electrode arrays for BCI applications.
Though FTD is not as well known as Alzheimer’s disease, it’s the second most common cause of dementia in people under 65, and there’s currently no treatment.
New UCSF research sheds light on how immune system B cells that infiltrate the central nervous system may drive multiple sclerosis.
UCSF scientists now have evidence from research that women with Alzheimer’s live longer than men with the disease because they have genetic protection from the ravages of the disease.
New research by neuroscientists at the University of Pittsburgh and UC San Francisco revealed that a simple, earbud-like device developed at UCSF that imperceptibly stimulates a key nerve leading to the brain could significantly improve the wearer’s ability to learn the sounds of a new language.
UCSF researchers are taking a closer look at COVID-19’s dizzying array of symptoms to get at the disease’s root causes.
Seniors who can identify smells like roses, turpentine, paint-thinner and lemons, and have retained their senses of hearing, vision and touch, may have half the risk of developing dementia as their peers with marked sensory decline, according to a new UCSF study.
A new study by UCSF researchers identified a surprising way that the brain’s immune cells help to form new memories.
Under a new agreement, Celgene will further invest in the RAN’s state-of-the-art antibody engineering program to expand target discovery from oncology and immunology to include neurology.